Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, international, multi-center, open label, stratified, exploratory phase
II study evaluating the efficacy and safety of lenvatinib in patients with
advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous
targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin
analogues (cohort B).